10.12.24 -- Cell & Gene Best Of September

FDA has released the new draft guidance for industry, Considerations for the Use of Human- and Animal-Derived Materials in the Manufacture of Cellular and Gene Therapy and Tissue-Engineered Medical Products. This article provides a summary — and shares what is shocking about the guidance.

Cell & Gene: The Podcast Host, Erin Harris, welcomes Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, for an in-depth interview about existing issues with current CAR T approaches, "auto versus allo," and why allogeneic is the path forward. They also discuss how and why allogeneic therapies are truly scalable.

Learn how to choose the right location — globally — for your next cell and gene therapy clinical trial.

This resource offers a detailed analysis of the global RNA trial landscape, highlighting the growth in trials, especially in the Asia-Pacific region, which has seen a 26% annual growth rate.

Find out how today’s FDA-approved obesity medications are primed to become tomorrow’s novel treatments across multidimensional states of disease — from diabetes to heart failure.

Explore insights from George Eastwood at the ThinkLive Cell and Gene Therapy Summit 2024 on enhancing therapies and advancing patient-centric drug development.